We are live on ! Find out more
VRTX icon

Vertex Pharmaceuticals
VRTX

1,687 hedge funds and large institutions have $106B invested in Vertex Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 151 funds opening new positions, 679 increasing their positions, 596 reducing their positions, and 104 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more first-time investments, than exits

New positions opened: 151 | Existing positions closed: 104

24% more call options, than puts

Call options by funds: $851M | Put options by funds: $684M

14% more repeat investments, than reductions

Existing positions increased: 679 | Existing positions reduced: 596

13% more funds holding in top 10

Funds holding in top 10: 15 → 17 (+2)

1% more funds holding

Funds holding: 1,668 → 1,687 (+19)

3% less capital invested

Capital invested by funds: $110B → $106B (-$3.45B)

1.71% less ownership

Funds ownership: 95.26% → 93.55% (-1.7%)

Holders
1,687
Holders Change
+19
Holders Change %
+1.14%
% of All Funds
20.76%
Holding in Top 10
17
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+13.33%
% of All Funds
0.21%
New
151
Increased
679
Reduced
596
Closed
104
Calls
$851M
Puts
$684M
Net Calls
+$167M
Net Calls Change
-$61.8M

Top Buyers

Rank Fund Capital Flow
1
Capital Research Global Investors
Capital Research Global Investors
California
+$1.78B
2
JP Morgan Chase
JP Morgan Chase
New York
+$463M
3
Goldman Sachs
Goldman Sachs
New York
+$310M
4
Capital International Investors
Capital International Investors
California
+$183M
5
Two Sigma Investments
Two Sigma Investments
New York
+$174M

Top Sellers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
-$685M
2
Winslow Capital Management
Winslow Capital Management
Minnesota
-$405M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$284M
4
AllianceBernstein
AllianceBernstein
Tennessee
-$273M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$242M
Name Holding Trade Value Shares
Change 		Change in
Stake
Victory Capital Management
26
Victory Capital Management
Texas
$843M -$685M -1,468,245 -44%
T. Rowe Price Associates
27
T. Rowe Price Associates
Maryland
$786M -$242M -518,836 -23%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$708M +$27.4M +58,841 +4%
Deutsche Bank
29
Deutsche Bank
Germany
$687M -$108M -231,145 -13%
Amundi
30
Amundi
France
$658M +$78.5M +168,335 +13%
VFT
31
Vanguard Fiduciary Trust
Pennsylvania
$655M +$683M +1,465,724 New
WCM Investment Management
32
WCM Investment Management
California
$497M -$3.64M -7,804 -0.7%
Royal Bank of Canada
33
Royal Bank of Canada
Ontario, Canada
$496M -$38.5M -82,641 -7%
N
34
Nuveen
North Carolina
$484M +$19.6M +42,098 +4%
Dimensional Fund Advisors
35
Dimensional Fund Advisors
Texas
$442M +$20.4M +43,682 +5%
Edgewood Management
36
Edgewood Management
Connecticut
$404M -$72.3M -154,946 -15%
BNP Paribas Asset Management
37
BNP Paribas Asset Management
France
$379M +$83.1M +178,240 +27%
American Century Companies
38
American Century Companies
Missouri
$363M -$16.5M -35,354 -4%
Wells Fargo
39
Wells Fargo
California
$333M +$1.48M +3,182 +0.4%
Swiss National Bank
40
Swiss National Bank
Switzerland
$332M +$19.6M +42,000 +6%
Citigroup
41
Citigroup
New York
$305M +$66.6M +142,877 +26%
BG
42
Bellevue Group
Switzerland
$304M +$367K +788 +0.1%
Barclays
43
Barclays
United Kingdom
$296M -$86M -184,495 -22%
HSBC Holdings
44
HSBC Holdings
United Kingdom
$293M +$11.7M +25,154 +4%
Arrowstreet Capital
45
Arrowstreet Capital
Massachusetts
$285M +$21M +45,003 +8%
UBS Group
46
UBS Group
Switzerland
$282M +$34.8M +74,636 +13%
Sumitomo Mitsui Trust Group
47
Sumitomo Mitsui Trust Group
Japan
$274M -$18.7M -40,022 -6%
Mitsubishi UFJ Asset Management
48
Mitsubishi UFJ Asset Management
Japan
$267M +$14.6M +31,270 +6%
VGA
49
Vanguard Global Advisers
Pennsylvania
$248M +$259M +555,733 New
Natixis Advisors
50
Natixis Advisors
Massachusetts
$247M +$12.2M +26,160 +5%
1
2
3 4 5

VRTX Hedge Fund Activity: Q1 2026 in Review

1,687 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2026, worth a combined $106B — down 3.2% from $110B a quarter earlier.

Buyers outnumbered sellers: 151 funds opened new VRTX positions and 104 closed out — a net gain of 47 holders — while 679 added to existing stakes and 596 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $1.78B. The largest seller was Victory Capital Management, cutting an estimated $685M.

  • 1,687 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2026, up from 1,668 in Q4 2025.
  • Funds reported $106B of Vertex Pharmaceuticals stock for Q1 2026, down 3.2% quarter-over-quarter.
  • 151 funds opened new Vertex Pharmaceuticals positions in Q1 2026 and 104 closed out, a net change of +47 holders.
  • The largest Vertex Pharmaceuticals buyer in Q1 2026 was Capital Research Global Investors, an estimated $1.78B added.
  • The largest Vertex Pharmaceuticals seller in Q1 2026 was Victory Capital Management, an estimated $685M sold.

Based on aggregated 13F filings for Q1 2026.